Targeting of Rifamycin SV to the Colon for Treatment of Travelers' Diarrhea: A Randomized, Double‐Blind, Placebo‐Controlled Phase 3 Study

ConclusionsRIF‐MMX shortened the duration of TD in patients with a broad range of pathogens and was well tolerated. The unique pharmacokinetic properties of the drug offer evidence that TD pathogens work at the level of the colon.

Source: Journal of Travel Medicine - October 27, 2014 Category: Infectious Diseases Authors: Herbert L. DuPont, AnnKatrin Petersen, Jeff Zhao, Arley Mundt, Zhi‐Dong Jiang, Stephan Miller, Jose Flores, Reshma Shringarpure, Luigi Moro, Robert G. Bagin, E. David Ballard, Mark C. Totoritis Tags: ORIGINAL ARTICLE Source Type: research